Jordyn Sava

Articles

G-CSF Allows for Efficacious Dose of Docetaxel With ARASENS Regimen in mHSPC

February 13th 2025

G-CSF use and docetaxel dose modifications allowed patients with mHSPC to receive efficacious doses of docetaxel in the ARASENS trial.

Lutetium Lu 177 Vipivotide Tetraxetan Plus Enzalutamide Boosts OS in mCRPC

February 13th 2025

Adding Lu-PSMA-617 to enzalutamide significantly improved overall survival and quality of life in metastatic castration-resistant prostate cancer.

Anakinra Fails to Reduce CRS, ICANS Associated With Liso-Cel in LBCL

February 13th 2025

Anakinra did not reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.

Talazoparib in Combination With Enzalutamide Improves OS in mCRPC

February 13th 2025

Talazoparib plus enzalutamide demonstrates improved overall survival in metastatic castration-resistant prostate cancer.

Frontline Nivolumab/Ipilimumab Prolongs OS in Unresectable HCC

January 24th 2025

Nivolumab plus ipilimumab produced a statistically significant and clinically meaningful OS benefit vs SOC in systemic therapy–naive unresectable HCC.

A 30-Year Commitment to Advancing Melanoma Care

January 1st 2025

Labeled as a strong and fair division chief, impactful mentor, and brilliant researcher, Lynn M. Schuchter, MD, continues to drive advances in melanoma with the aid of a collaborative and innovative atmosphere.

Perioperative Atezolizumab Plus Chemo Does Not Improve EFS in TNBC

December 13th 2024

Treatment with atezolizumab and neoadjuvant chemotherapy followed by adjuvant atezolizumab did not improve EFS in triple-negative breast cancer.

Optimizing Treatment Sequences Remains Key in CLL/SLL

December 12th 2024

Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.

Adjuvant Olaparib Maintains iDFS Benefit in BRCA1/2+, HER2– Breast Cancer

December 11th 2024

Adjuvant olaparib maintained an efficacy benefit vs placebo in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer.

Potential Biomarkers Positively Prognosticate Outcomes With Pembrolizumab Plus Chemo in High-Risk TNBC

December 11th 2024

Pembrolizumab plus chemotherapy conferred an efficacy advantage over chemotherapy alone in high-risk TNBC subgroups defined by potential biomarkers.

Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL

December 10th 2024

Axi-cel sustained long-term efficacy in relapsed/refractory follicular lymphoma and marginal zone lymphoma.

Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma

December 10th 2024

Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.

Uproleselan Plus Chemo Fails to Produce OS Benefit in Relapsed/Refractory AML

December 9th 2024

The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.

Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma

December 9th 2024

Tisagenlecleucel maintained long-term efficacy and safety in relapsed/refractory follicular lymphoma.

Maintenance Teclistamab With or Without Lenalidomide Is Safe, Active in Newly Diagnosed Myeloma

December 9th 2024

Maintenance therapy with teclistamab with or without lenalidomide was safe and efficacious in newly diagnosed multiple myeloma.

Isa-KRd Induction Therapy Elicits Responses, MRD Negativity in Transplant-Eligible, Newly Diagnosed Myeloma

September 27th 2024

Patients with newly diagnosed, transplant-eligible multiple myeloma achieved deep responses and MRD negativity with isa-KRd induction therapy.

Adjuvant Pembrolizumab Prolongs DFS Regardless of PD-L1 or Nodal Status in High-Risk MIBC

September 25th 2024

Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.

Several IO Combos Miss Efficacy Target in NSCLC, But Clinical Benefit Seen With 2 Combos

September 16th 2024

Durvalumab plus monalizumab and durvalumab plus ceralasertib showed promising long-term benefits in advanced NSCLC.

Abemaciclib/ET Combo Improves Responses vs Chemo in Aggressive HR+/HER2– Breast Cancer

September 16th 2024

Frontline abemaciclib plus ET demonstrated a superior ORR vs chemotherapy in HR+/HER2– advanced breast cancer with aggressive disease characteristics.

RP1 Plus Nivolumab Demonstrates Durable Antitumor Activity in Advanced Melanoma

September 15th 2024

RP1 plus nivolumab offers durable responses and a favorable safety profile for patients with melanoma after progression on anti–PD-1 therapy.